Veracyte Inc VCYT:NASDAQ

Last Price$24.66NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/23/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$22.63 (2)
Ask (Size)$26.33 (10)
Day Low / HighN/A - N/A
Volume310.6 K
 

View Biotechnology IndustryPeer Comparison as of 08/23/2019

 

Veracyte Inc ( NASDAQ )

Price: $24.66
Change: -0.64 (2.53%)
Volume: 310.6 K
4:00PM ET 8/23/2019
 
 

Editas Medicine Inc ( NASDAQ )

Price: $24.06
Change: -1.23 (4.86%)
Volume: 585.6 K
4:00PM ET 8/23/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.02
Change: -0.20 (1.64%)
Volume: 469.6 K
4:15PM ET 8/23/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $19.36
Change: -0.97 (4.77%)
Volume: 542.4 K
4:00PM ET 8/23/2019
 
 

Epizyme Inc ( NASDAQ )

Price: $12.86
Change: -0.42 (3.16%)
Volume: 487.0 K
4:00PM ET 8/23/2019
 

Read more news Recent News

Insider Trends: Veracyte Sees 90 Days of Insider Buying Trend Slowing with Share Sale
4:26PM ET 8/12/2019 MT Newswires

Evan Jones, Director, sold 15,000 shares of Veracyte (VCYT) on Aug 09, 2019, for $395,681. Following the Form 4 filing with the SEC, Jones controls a...

Insider Trends: Insider at Veracyte Converts Options in Mist of 90-Day Buying Trend
4:20PM ET 8/05/2019 MT Newswires

Fred E Cohen, Director, exercised options for 40,000 shares in Veracyte (VCYT) for $368,200 on Aug 02, 2019. Cohen, following the transactions detailed in...

--Analyst Actions: Janney Raises Price Target on Veracyte to $33 From $27, Maintains Buy Rating
8:49AM ET 7/31/2019 MT Newswires

Price: 29.61, Change: 0.00, Percent Change: 0.00 ...

Veracyte Posts Narrower Q2 Loss vs Estimate, Revenue Narrowly Beats Forecast; Lifts FY2019 Revenue Outlook
6:39AM ET 7/31/2019 MT Newswires

Veracyte (VCYT) reported late Tuesday Q2 net loss of $0.05 per share compared to a net loss of $0.18 per share in the year-ago period. Wall Street analysts...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing08/14/20194
Chairman & Chief Executive OfficerBonnie H. Anderson
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Chief Information OfficerAshish Kheterpal

Company Highlights

Price Open$25.10
Previous Close$25.30
52 Week Range$8.77 - 31.18
Market Capitalization$1.2 B
Shares Outstanding48.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/04/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.29
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-11.01%
Return on Equity-10.26%

Analyst Ratings as of 07/31/2019

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset